So Far So Good: With Phase III Data, Keryx Says Zerenex Will Stand Out In ESRD Crowd
This article was originally published in The Pink Sheet Daily
Company set to price drug up to 20% below Genzyme's market leading Renvela/Renagel franchise, and ponders impact of new Medicare bundling regime for phosphate binders used in end-stage renal disease.
You may also be interested in...
Recently-approved (and still un-trade named) phosphate binder ferric citrate could unseat the market leader due to its unique ability to increase iron in patients, firm believes, although it didn’t get the full set of labeling claims it sought.
Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.
Phase III data readout on perifosine in colorectal cancer patients will spark a partnership or acquisition, CEO Ron Bentsur predicts during a Q2 call.